$10.17
-0.37[-3.51%]
At close: Apr 25
$10.17
0[0.00%]
After Hours: 4:20PM EDT
Amicus Therapeutics
(NASDAQ:FOLD)Amicus Therapeutics Stock (NASDAQ:FOLD), Analyst Ratings, Price Targets, Predictions
Amicus Therapeutics Inc has a consensus price target of $15.25, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Cantor Fitzgerald, and Morgan Stanley on March 18, 2024, February 29, 2024, and December 19, 2023. With an average price target of $20.33 between JP Morgan, Cantor Fitzgerald, and Morgan Stanley, there's an implied 99.93% upside for Amicus Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Cantor Fitzgerald
Morgan Stanley
Morgan Stanley
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Amicus Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 86.82% | JP Morgan | Anupam Rama | $21 → $19 | Maintains | Overweight | Get Alert |
| 02/29/2024 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 116.32% | Cantor Fitzgerald | Kristen Kluska | → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 96.66% | Morgan Stanley | Jeffrey Hung | $15 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/09/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 47.49% | Morgan Stanley | Andrew Galler | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 37.66% | Morgan Stanley | Andrew Galler | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 09/29/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 86.82% | JP Morgan | Anupam Rama | $17 → $19 | Maintains | Overweight | Get Alert |
| 07/11/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 47.49% | Morgan Stanley | Andrew Galler | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 03/28/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 67.16% | B of A Securities | Tazeen Ahmad | $16 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 67.16% | UBS | Karl Chalabala | $15 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 8.16% | Goldman Sachs | Salveen Richter | $10 → $11 | Maintains | Neutral | Get Alert |
| 01/18/2023 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 57.33% | BTIG | Yun Zhong | $14 → $16 | Maintains | Buy | Get Alert |
| 11/08/2022 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 47.49% | Morgan Stanley | Andrew Galler | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 37.66% | Morgan Stanley | Andrew Galler | → $14 | Initiates | → Equal-Weight | Get Alert |
| 02/24/2022 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 37.66% | SVB Leerink | Joseph Schwartz | $16 → $14 | Maintains | Outperform | Get Alert |
| 01/14/2022 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 57.33% | SVB Leerink | Joseph Schwartz | $12 → $16 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/13/2022 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 47.49% | Cantor Fitzgerald | Kristen Kluska | $16 → $15 | Maintains | Overweight | Get Alert |
| 11/15/2021 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 57.33% | Stifel | Dae Gon Ha | — | Upgrade | Hold → Buy | Get Alert |
| 09/30/2021 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 57.33% | JP Morgan | Anupam Rama | — | Upgrade | Neutral → Overweight | Get Alert |
| 09/30/2021 | FOLD | Buy Now | Amicus Therapeutics | $10.17 | 17.99% | SVB Leerink | Joseph Schwartz | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Amicus Therapeutics (FOLD)?
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by JP Morgan on March 18, 2024. The analyst firm set a price target for $19.00 expecting FOLD to rise to within 12 months (a possible 86.82% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by JP Morgan, and Amicus Therapeutics maintained their overweight rating.
When was the last upgrade for Amicus Therapeutics (FOLD)?
The last upgrade for Amicus Therapeutics Inc happened on December 19, 2023 when Morgan Stanley raised their price target to $20. Morgan Stanley previously had an equal-weight for Amicus Therapeutics Inc.
When was the last downgrade for Amicus Therapeutics (FOLD)?
There is no last downgrade for Amicus Therapeutics.
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $21.00 to $19.00. The current price Amicus Therapeutics (FOLD) is trading at is $10.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.